Acinetobacter baumannii complex

From IDWiki
Acinetobacter baumannii complex /
Revision as of 02:33, 14 November 2024 by Aidan (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Background

Microbiology

Antimicrobial Resistance

  • A number of mechanisms
  • Carbapenem resistance is usually mediated by acquisition of OXA-type class D carbapenemase
    • Less common mechanisms include acquisition of class B (VIM, IMP, and NDM) carbapenemases, loss of outer membrane CarO protein, and modification of AdeABC efflux pump

Management

Carbapenem-Resistant Acinetobacter baumannii

  • Infection must be distinguished from colonization of the airway or wound
  • Resistance may be mediated by a number of β-lactamases, including OXA-24/40-like carbapenemases, OXA-23-like carbapenemases, and metallo-β-lactamases, and often has sulbactam resistance
  • Often have concurrent aminoglycoside-modifying enzymes or 16S rRNA methyltransferases, which confer resistance to aminoglycosides including plazomicin
  • Refer to ESCMID guidelines1
  • Single-agent treatment may be sufficient for mild infections
  • Combination treatment with at least two agents that have in vitro activity for most other infections
  • Cefiderocol should generally be avoided

References

  1. ^  Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli, Jesús Rodríguez-Baño. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025.